Location History:
- Kobe, JP (1995 - 1997)
- Toyonaka, JP (2020 - 2023)
Company Filing History:
Years Active: 1995-2023
Title: Etsuo Nakamura: Innovator in Monoclonal Antibody Development
Introduction
Etsuo Nakamura is a prominent inventor based in Toyonaka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 5 patents to his name, Nakamura's work focuses on innovative solutions for medical treatments.
Latest Patents
Nakamura's latest patents include a monoclonal antibody against Nav1.7. The objective of this invention is to provide a novel monoclonal antibody that can be used for treating or preventing pain and pruritus. This invention discloses a monoclonal antibody or its antibody fragment, characterized by specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain). Another significant patent involves a method for the treatment or prevention of diseases related to vascular endothelial lipase. This patent provides a humanized monoclonal antibody that selectively inhibits the enzymatic activity of vascular endothelial lipase, offering potential treatments for arteriosclerosis and metabolic syndrome.
Career Highlights
Etsuo Nakamura is currently associated with Shionogi Company Limited, where he continues to advance his research and development efforts. His work has been instrumental in the field of therapeutic antibodies, contributing to innovative medical solutions.
Collaborations
Nakamura has collaborated with notable colleagues, including Shoichi Naito and Hiroaki Aino. These partnerships have enhanced the scope and impact of his research in the biotechnology sector.
Conclusion
Etsuo Nakamura's contributions to monoclonal antibody development highlight his role as a key innovator in biotechnology. His patents reflect a commitment to advancing medical treatments and improving patient care.